{"id":447,"date":"2022-05-20T20:14:40","date_gmt":"2022-05-20T18:14:40","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=447"},"modified":"2022-05-20T20:43:18","modified_gmt":"2022-05-20T18:43:18","slug":"afamelanotide-appeal-not-addressed-in-england","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/","title":{"rendered":"Afamelanotide in England: Appeal outcomes not addressed for more than three years"},"content":{"rendered":"\n<p>The possibility to appeal against a negative funding recommendation for technologies evaluated by the National Institute for Health and Care Excellence (NICE) in England was established to ensure fairness in their decision-making and priority-setting. However, more than three years after an appeal lodged during the appraisal proceedings of afamelanotide for treating erythropoietic protoporphyria (EPP), the points raised by concerned stakeholders, including the IPPN, and upheld by the appeal panel have yet to be addressed and, regrettably, patients with EPP in England remain without access to the only treatment for their condition.<\/p>\n\n\n\n<p>To raise awareness in the scientific community about this issue, the IPPN has published their experience with NICE in a peer-reviewed, open access article in the medical journal Disability &amp; Society:<\/p>\n\n\n\n<p>\u2018\u2026 they had interpreted \u201cdisability\u201d as referring to a patently visible disability\u2019: experience of a patient group with NICE:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09687599.2022.2060804\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09687599.2022.2060804<\/a><\/p>\n\n\n\n<p>With this publication we hope to promote a more fair, consistent, and respectful evaluation process for patients with EPP and other conditions at NICE.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The possibility to appeal against a negative funding recommendation for technologies evaluated by the National Institute for Health and Care Excellence (NICE) in England was established to ensure fairness in their decision-making and priority-setting. However, more than three years after an appeal lodged during the appraisal proceedings of afamelanotide for treating erythropoietic protoporphyria (EPP), the&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network<\/title>\n<meta name=\"description\" content=\"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-20T18:14:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-20T18:43:18+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"Afamelanotide in England: Appeal outcomes not addressed for more than three years\",\"datePublished\":\"2022-05-20T18:14:40+00:00\",\"dateModified\":\"2022-05-20T18:43:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\"},\"wordCount\":182,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\",\"name\":\"Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2022-05-20T18:14:40+00:00\",\"dateModified\":\"2022-05-20T18:43:18+00:00\",\"description\":\"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Afamelanotide in England: Appeal outcomes not addressed for more than three years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network","description":"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/","og_locale":"en_US","og_type":"article","og_title":"Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network","og_description":"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement","og_url":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2022-05-20T18:14:40+00:00","article_modified_time":"2022-05-20T18:43:18+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"Afamelanotide in England: Appeal outcomes not addressed for more than three years","datePublished":"2022-05-20T18:14:40+00:00","dateModified":"2022-05-20T18:43:18+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/"},"wordCount":182,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/","url":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/","name":"Afamelanotide in England: Appeal outcomes not addressed for more than three years - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2022-05-20T18:14:40+00:00","dateModified":"2022-05-20T18:43:18+00:00","description":"International Porphyria Patient Network Afamelanotide National Institute for Health and Care Excellence England Protoporphyria Reimbursement","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2022\/05\/afamelanotide-appeal-not-addressed-in-england\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"Afamelanotide in England: Appeal outcomes not addressed for more than three years"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/447"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":449,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/447\/revisions\/449"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}